A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies.

Trial Profile

A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 May 2009

At a glance

  • Drugs Barasertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors AstraZeneca
  • Most Recent Events

    • 20 May 2009 Planned end date (Jul 2007) added as reported by ClinicalTrials.gov.
    • 12 Mar 2008 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 09 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top